Market Overview

Deutsche Bank Comments On Stryker Following Solid Earnings Report

Share:

Stryker's (NYSE: SYK) 1Q sales were in line with Consensus at $2.0B, up 12% reported and 10% ex-FX. Underlying hip and knee sales were below Deutsche Bank's estimate and likely the Street. However, MedSurg made up the difference. After adjusting for acquisitions and FX, sales were up just 4%--far from an impressive quarter but likely in line with the broader MedTech market. EPS rose 12.5% to $0.90 and were $0.01 ahead. Given the stock's relative premium valuation, Deutsche Bank sees the stock as fully valued and as it maintains a Hold and $61 PT.

Commentary suggests price stability and incrementally better mix better thus absent major market share movements from Zimmer and S&N unit volumes decelerated. While Deutsche Bank believes the volumes will recover, it thinks a recovery is farther off than the market expects and the magnitude may also be less as we expect net price/mix to remain negative.

Orthopedic sales were weaker though sales of MedSurg were better. However, net/net organic sales were up just 4% in the quarter. Total company pricing was down 1.9%, which was better than the 2.1% in 4Q though Deutsche Bank chalks it up to a greater MedSurg mix which has better pricing dynamics rather than a sign that ortho pricing is improving.

SYK closed Tuesday at $61.10

 

Related Articles (SYK)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
PECFRAMaintains8.0
HUNCFRAUpgrades16.0
CCCFRADowngrades11.0
VOYAPiper SandlerMaintains58.0
PRUPiper SandlerMaintains64.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com